{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:00:55Z","timestamp":1792051255214,"version":"4.4.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are limited data regarding therapeutic drug monitoring (TDM) of non-anti-tumor necrosis factor therapy in inflammatory bowel disease (IBD). This study aimed to evaluate the efficacy of proactive TDM in IBD patients treated with intravenous (iv) vedolizumab (VDZ).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This single-center retrospective cohort study included consecutive IBD patients treated with maintenance iv VDZ therapy undergoing TDM from November 2016 to March 2023. Patients were followed through June 2023 and were divided in to 2 groups: those who had at least 1 proactive TDM vs those who underwent only reactive TDM. A survival analysis was performed to evaluate drug persistence, defined as no need for drug discontinuation due to loss of response, serious adverse event, or an IBD-related surgery.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study population consisted of 94 patients (proactive TDM, n\u2005=\u200572) with IBD (ulcerative colitis, n\u2005=\u200553). Patients undergoing at least 1 proactive TDM compared with patients having only reactive TDM demonstrated a higher cumulative probability of drug persistence (Log-rank P &amp;lt; .001). In multivariable Cox proportional hazard regression analysis, at least 1 proactive TDM was the only factor associated with drug persistence (hazard ratio, 14.3; 95% confidence interval [CI], 3.8-50; P &amp;lt; .001). A ROC analysis identified a VDZ concentration of 12.5 \u00b5g\/mL as the optimal drug concentration threshold associated with drug persistence (area under the ROC curve: 0.691; 95% CI, 0.517-0.865; P = .049).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this single-center retrospective study reflecting real-life clinical practice, proactive TDM was associated with increased drug persistence in patients with IBD treated with iv VDZ.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae140","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T22:59:22Z","timestamp":1719961162000},"page":"485-491","source":"Crossref","is-referenced-by-count":13,"title":["Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab"],"prefix":"10.1093","volume":"31","author":[{"given":"Rachel","family":"Porth","sequence":"first","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Deyhim","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Zullow","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren G","family":"Rabinowitz","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie B","family":"Grossberg","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital of Saint-Etienne , Saint-Etienne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-4273","authenticated-orcid":false,"given":"Stephane","family":"Paul","sequence":"additional","affiliation":[{"name":"Immunology laboratory, CIC1408, University Hospital of Saint-Etienne , Saint-Etienne ,","place":["France"]},{"name":"CIRI (Centre International de Recherche en Infectiologie), Universit\u00e9 Claude Bernard Lyon 1, INSERM U1111, CNRS, UMR5308, ENS Lyon, Universit\u00e9 Jean Monnet de Saint-Etienne , 10 Rue Tr\u00e9filerie, 42100 Saint-Etienne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S","family":"Cheifetz","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1497-0254","authenticated-orcid":false,"given":"Konstantinos","family":"Papamichael","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,2]]},"reference":[{"issue":"12","key":"2025021012303672700_CIT0001","first-page":"656","article-title":"Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)."},{"issue":"10","key":"2025021012303672700_CIT0002","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.14309\/ajg.0000000000001396","article-title":"A comprehensive literature review and expert consensus statement on therapeutic drug monitoring of biologics in inflammatory bowel disease","volume":"116","author":"Cheifetz","year":"2012","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2025021012303672700_CIT0003","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"10","key":"2025021012303672700_CIT0004","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","article-title":"Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab","volume":"15","author":"Papamichael","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"12","key":"2025021012303672700_CIT0005","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1111\/apt.17313","article-title":"Meta-analysis: the efficacy of therapeutic drug monitoring of anti-TNF-therapy in inflammatory bowel disease","volume":"57","author":"Sethi","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"2025021012303672700_CIT0006","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","article-title":"Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease","volume":"13","author":"Papamichael","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"4","key":"2025021012303672700_CIT0007","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1053\/j.gastro.2019.06.003","article-title":"Proactive monitoring of adalimumab trough concentration associated with increased clinical remission in children with Crohn\u2019s disease compared with reactive monitoring","volume":"157","author":"Assa","year":"2019","journal-title":"Gastroenterology."},{"issue":"2","key":"2025021012303672700_CIT0008","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik","year":"2021","journal-title":"Scand J Gastroenterol."},{"issue":"5","key":"2025021012303672700_CIT0009","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/pharmaceutics14051009","article-title":"Cost-effectiveness of therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease: a systematic review","volume":"14","author":"Marquez-Megias","year":"2022","journal-title":"Pharmaceutics."},{"issue":"2","key":"2025021012303672700_CIT0010","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2468-1253(21)00223-5","article-title":"Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives","volume":"7","author":"Papamichael","year":"2022","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"8","key":"2025021012303672700_CIT0011","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/apt.15484","article-title":"Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases","volume":"50","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2025021012303672700_CIT0012","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1111\/apt.16937","article-title":"Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure\u2013response relationship of vedolizumab in inflammatory bowel disease: ERELATE study","volume":"56","author":"Vande Casteele","year":"2022","journal-title":"Aliment Pharmacol Ther."},{"issue":"8","key":"2025021012303672700_CIT0013","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/ecco-jcc\/jjx021","article-title":"Exposure\u2013efficacy relationships for vedolizumab induction therapy in patients with ulcerative colitis or Crohn\u2019s disease","volume":"11","author":"Rosario","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2025021012303672700_CIT0014","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/jgh.16518","article-title":"Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease","volume":"39","author":"Steenholdt","year":"2024","journal-title":"J Gastroenterol Hepatol."},{"key":"2025021012303672700_CIT0015","first-page":"38","article-title":"Relationship between vedolizumab serum concentrations in the induction phase and early and sustained response in the first year of treatment in patients with ulcerative colitis","volume-title":"Farm Hosp.","author":"S\u00e1nchez-Hern\u00e1ndez","year":"2021"},{"issue":"1","key":"2025021012303672700_CIT0016","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3390\/jcm13010140","article-title":"Efficacy and safety of vedolizumab in patients with inflammatory bowel disease in association with vedolizumab drug levels","volume":"13","author":"H\u00fcttemann","year":"2023","journal-title":"J Clin Med."},{"issue":"8","key":"2025021012303672700_CIT0017","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1093\/ecco-jcc\/jjz041","article-title":"Higher trough vedolizumab concentrations during maintenance therapy are associated with corticosteroid-free remission in inflammatory bowel disease","volume":"13","author":"Ungaro","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"11","key":"2025021012303672700_CIT0018","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months","volume":"15","author":"Williet","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"5","key":"2025021012303672700_CIT0019","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cgh.2023.10.02","article-title":"ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse","volume":"22","author":"Jairath","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2025021012303672700_CIT0020","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/jpn3.12132","article-title":"Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease","volume":"78","author":"Patrick Rowland","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr."},{"issue":"11","key":"2025021012303672700_CIT0021","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1016\/j.cgh.2022.10.037","article-title":"Prior antibodies to infliximab or adalimumab are related to immunogenicity to vedolizumab in patients with inflammatory bowel disease","volume":"21","author":"Papamichael","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2025021012303672700_CIT0022","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2025021012303672700_CIT0023","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ecco-jcc\/jjz151","article-title":"Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF na\u00efve and anti-TNF exposed IBD patients","volume":"14","author":"Verstockt","year":"2020","journal-title":"J Crohns Colitis."},{"issue":"12","key":"2025021012303672700_CIT0024","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2025021012303672700_CIT0025","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FTD.0000000000001068","article-title":"Measuring serum vedolizumab and vedolizumab antibodies: comparison of commercial assays with the vedolizumab clinical development assay","volume":"45","author":"Vande Casteele","year":"2023","journal-title":"Ther Drug Monit."},{"issue":"4","key":"2025021012303672700_CIT0026","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.cgh.2020.03.002","article-title":"Comparison of assays for therapeutic monitoring of infliximab and adalimumab in patients with inflammatory bowel diseases","volume":"19","author":"Papamichael","year":"2021","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae140\/58390976\/izae140.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/2\/485\/58390976\/izae140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/2\/485\/58390976\/izae140.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T12:38:08Z","timestamp":1739191088000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/2\/485\/7702721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,2]]},"published-print":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae140","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,7,2]]}}}